Winona Medical Leadership and Credentials: An Independent Review

Who Leads Winona Clinically?

Winona's website lists a Chief Medical Officer and a medical advisory board, but the company does not publish individual physician NPI numbers, board-certification details, or state license numbers in a single publicly verifiable document. Patients who want to confirm credentials independently can query the National Plan and Provider Enumeration System (NPPES) at npiregistry.cms.hhs.gov or the relevant state medical board.

What Winona Says About Its Physicians

According to Winona's public materials, all prescribers are licensed in the state where the patient resides and have experience in women's health or internal medicine. The company states that physicians review each intake questionnaire before any prescription is issued. This asynchronous review model is common in telehealth but differs from a traditional synchronous office visit.

What Independent Verification Looks Like

Board certification can be confirmed through the American Board of Medical Specialties at abms.org or the American Board of Obstetrics and Gynecology at abog.org. Neither Winona nor any third-party aggregator publishes a complete, current list of Winona physicians with linked verification. That gap is a limitation patients should weigh before enrolling.

The Federation of State Medical Boards maintains a physician finder at fsmb.org that allows patients to check for disciplinary actions. HealthRX recommends running your assigned prescriber's name through that tool after your first consultation.

Is Winona Legit? Licensing, Accreditation, and Regulatory Standing

Short answer: Winona operates as a licensed telehealth business in the states it serves, and its compounding pharmacy partners are state-licensed. "Legit" in the regulatory sense is not a binary label, though. There are meaningful compliance nuances worth understanding.

Telehealth Licensing

Telehealth platforms must hold or partner with licensed medical entities in each state where they prescribe. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [codified at 21 U.S.C. 829(e)] requires that a prescriber conduct at least one in-person medical evaluation before prescribing controlled substances via the internet, with temporary DEA waivers in place through 2025 for telemedicine [see FDA guidance at fda.gov]. Hormone therapies such as estradiol and progesterone are not scheduled controlled substances, so the Ryan Haight Act does not directly apply, but state telehealth statutes do.

Compounding Pharmacy Status

Winona uses 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 353a, accessible via fda.gov] exempts these pharmacies from FDA's new drug approval requirements and certain labeling requirements, provided they compound on a patient-specific prescription basis. This means compounded estradiol or progesterone from a 503A pharmacy has not undergone the same clinical trial review as FDA-approved products such as Estrace (estradiol tablets) or Prometrium (oral micronized progesterone).

The FDA has published guidance distinguishing 503A pharmacies from 503B outsourcing facilities. A 503B facility is FDA-registered and subject to current Good Manufacturing Practice inspections; a 503A pharmacy is not. Winona's pharmacy partners appear to be 503A, not 503B. Patients can verify whether a compounding pharmacy has received FDA warning letters by searching fda.gov/drugs/human-drug-compounding/compounding-warning-letters.

LegitScript and BBB Standing

LegitScript is an independent certification body used by Google, Facebook, and other platforms to verify that online pharmacies and telehealth services operate legally. Winona's LegitScript status should be confirmed directly at legitscript.com because certification status changes. As of this writing, Winona is not listed as BBB-accredited, and its BBB profile shows a rating that prospective patients can check at bbb.org. A lack of BBB accreditation is not equivalent to a finding of wrongdoing, but it does mean the company has not committed to BBB's standards of responsiveness.

What the FDA Says About Compounded Bioidentical Hormones

The FDA has issued multiple statements expressing concern about compounded bioidentical hormone therapy (cBHT). The agency's 2020 draft guidance on cBHT [available at fda.gov] notes that claims of superior safety or customization for cBHT are not supported by clinical evidence compared to FDA-approved hormone products.

The NASEM Report

In 2020, the National Academies of Sciences, Engineering, and Medicine (NASEM) published a report titled "The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use." The report concluded that evidence is insufficient to conclude that cBHT is safe or effective for any condition. The FDA cited this report in subsequent guidance. Patients can read the full report summary at ncbi.nlm.nih.gov/books/NBK562761/.

FDA-Approved Alternatives Winona Could Prescribe

FDA-approved bioidentical options exist. Estrace (17-beta estradiol) and Vivelle-Dot (estradiol patch) are FDA-approved bioidentical estradiol products. Prometrium is FDA-approved oral micronized progesterone. The Menopause Society's 2022 Position Statement on hormone therapy [available at menopause.org] states: "FDA-approved hormone therapy products are preferred over compounded hormone therapies because they have undergone rigorous testing for safety, efficacy, and quality." Winona's prescribers may offer both compounded and FDA-approved options depending on clinical need; patients should ask explicitly which category any prescribed product falls into.

Clinical Guidelines Governing Menopause HRT

The Menopause Society 2022 Position Statement

The Menopause Society (formerly the North American Menopause Society, NAMS) published its 2022 Hormone Therapy Position Statement in the journal Menopause [doi: 10.1097/GME.0000000000002028, accessible at pubmed.ncbi.nlm.nih.gov/35797481/]. The statement establishes that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for healthy women under age 60 or within 10 years of menopause onset when benefits outweigh risks.

The statement also notes: "The risk of breast cancer from hormone therapy use is low (less than 1 per 1,000 women per year) and similar to the risk associated with lifestyle factors such as physical inactivity or alcohol consumption."

Any telehealth platform offering HRT, including Winona, should be screening patients against contraindications listed in this statement: undiagnosed vaginal bleeding, active liver disease, personal history of estrogen-sensitive malignancy, prior venous thromboembolism, or active cardiovascular disease.

WHI and Its Reinterpretation

The Women's Health Initiative (WHI) trial, published in JAMA in 2002 [accessible at jamanetwork.com/journals/jama/fullarticle/195120], generated significant concern about HRT. The WHI enrolled 16,608 postmenopausal women aged 50 to 79 years and found an increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism in the conjugated equine estrogen plus medroxyprogesterone acetate arm compared to placebo.

Subsequent re-analysis by Manson et al., published in JAMA in 2017 (N=27,347, jamanetwork.com/journals/jama/fullarticle/2655534), showed that younger women aged 50 to 59 years had a 32% lower risk of all-cause mortality with hormone therapy compared to placebo. The risk-benefit calculation is age-dependent. A telehealth platform should be applying this nuance, not offering hormone therapy to every woman who requests it.

The Timing Hypothesis

The "timing hypothesis" or "window of opportunity" concept holds that HRT initiated within 10 years of menopause or before age 60 carries a more favorable cardiovascular risk profile than HRT started later. This concept was supported by data from the Kronos Early Estrogen Prevention Study (KEEPS), results of which were published in Climacteric in 2014 pubmed.ncbi.nlm.nih.gov/25169441/. Any prescriber on Winona's platform should be accounting for a patient's years since menopause, not just her symptom burden.

Winona Complaints: What Patients Report

Patient complaints about Winona fall into several recurring categories based on publicly available reviews on the BBB website, Trustpilot, and Reddit forums. HealthRX does not verify individual patient accounts, but pattern analysis of complaints is clinically informative.

Billing and Subscription Issues

The most common complaint category involves difficulty canceling subscriptions and unexpected charges. The BBB complaint portal bbb.org shows multiple unresolved complaints in this area. This is a business-practice issue, not a clinical safety issue, but it affects patient trust and continuity of care. Patients who discontinue a subscription abruptly may also stop HRT abruptly, which can cause symptom rebound.

Asynchronous Care Limitations

Several patients report that they submitted intake questionnaires and received prescriptions without speaking to a physician. Asynchronous prescribing is legal in many states but carries risk when a patient has complex comorbidities. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 on menopause acog.org does not explicitly endorse or prohibit asynchronous prescribing, but it does state that a thorough history and physical assessment are components of appropriate menopause management.

Compounding Quality Variation

A smaller number of complaints describe inconsistent product appearance or potency between refill batches. Compounded products do not have the same batch-to-batch consistency requirements as FDA-approved drugs. The FDA's inspection database for 503A pharmacies is not comprehensive, meaning patients cannot easily verify a compounding pharmacy's recent inspection history unless a warning letter has been issued.

Positive Reports

Positive reviews frequently mention cost savings compared to traditional gynecology visits, fast turnaround on prescriptions, and access for patients in areas with limited gynecological care. These are real access benefits. The out-of-pocket cost of a Winona subscription is typically lower than a cash-pay specialist visit, and geographic access to menopause-specialist physicians is genuinely limited: a 2023 analysis cited by The Menopause Society found fewer than 1,000 certified menopause practitioners in the United States for a population of approximately 6,000 women entering menopause daily.

How Winona's Model Compares to Clinical Best Practice

Intake Process

Best practice per The Menopause Society 2022 statement includes a full menstrual history, symptom severity scoring (using a validated tool such as the Menopause Rating Scale), review of personal and family cancer history, cardiovascular risk assessment, and measurement or review of blood pressure. Winona's asynchronous intake questionnaire covers many of these elements, but a written questionnaire cannot substitute for the clinical judgment applied during a synchronous visit when a patient's answers raise red flags.

Laboratory Testing

The Endocrine Society's clinical practice guideline on menopause pubmed.ncbi.nlm.nih.gov/25785264/ does not recommend routine hormone level testing before initiating HRT in symptomatic perimenopausal women, because levels fluctuate widely. Winona's approach of prescribing without baseline labs is therefore consistent with guideline recommendations for most patients. However, certain situations, such as suspected premature ovarian insufficiency in a woman under 40, require FSH and estradiol measurements before prescribing.

Follow-Up Cadence

The Menopause Society recommends annual reassessment of HRT need and risk. Whether Winona's platform enforces annual reassessment encounters or allows subscriptions to auto-renew without clinical check-in is a meaningful quality differentiator. Patients should confirm this explicitly when enrolling.

Questions to Ask Before Enrolling in Winona

Before submitting a Winona intake form, a prospective patient should have clear answers to five specific questions.

First: Is the prescriber who will review my form board-certified in obstetrics and gynecology, internal medicine, or a related specialty, and can I verify that certification independently?

Second: Will I receive a compounded product or an FDA-approved product, and if compounded, which 503A pharmacy will fill the prescription?

Third: Is that pharmacy currently free of FDA warning letters (searchable at fda.gov/drugs/human-drug-compounding/compounding-warning-letters)?

Fourth: What is the process for a synchronous visit if I develop new symptoms or side effects after starting HRT?

Fifth: How do I cancel, and will cancellation stop automatic charges within one billing cycle?

These are not hostile questions. They are standard due-diligence questions any board-certified physician would expect a well-informed patient to ask.